BioSpace News Archive

Sesen Bio today announced its anticipated regulatory path forward for Vicineum™ or the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) following its Clinical Type A meeting with the US Food and Drug Administration (FDA), which occurred on December 8, 2021 (Clinical Type A Meeting).

BlueCube Bio officially announced a company name transition to Evia Bio™, concurrent with the launch of a significant new cryopreservation technology for use in cell and gene therapies utilizing Induced Pluripotent Stem Cells (iPSCs).

Cyclo Therapeutics Appoints Caroline Hastings, M.D. as Global Principal Investigator for Ongoing TransportNPC™ Study Evaluating Trappsol ® Cyclo™ for the Treatment of Niemann-Pick Disease.

Mustang Bio, Inc. today announced that it will host a key opinion leader (“KOL”) webinar on MB-106, the Company’s CD20-targeted, autologous CAR T cell therapy for the treatment of B-cell non-Hodgkin lymphomas (“B-NHLs”) and chronic lymphocytic leukemia (“CLL”), on Thursday, December 16, 2021, at 2:30 p.m. Eastern Time.

Berkeley Lights, Inc., a leader in digital cell biology, announced its participation at the upcoming Antibody Engineering & Therapeutics meeting, being held virtually and in person from Dec. 12-16, 2021, in San Diego, California.

Acer Therapeutics Inc. today announced U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application for its selective non-peptide neurokinin 3 receptor (NK3R) antagonist, ACER-801 (osanetant), for the potential treatment of induced Vasomotor Symptoms (iVMS).

Beyond Air, Inc. announced an update to the expectations for U.S. Food and Drug Administration approval of LungFit® PH for the treatment of persistent pulmonary hypertension of the newborn, or PPHN.

Emmaus Life Sciences, Inc.today announced that Yutaka Niihara, M.D., M.P.H., Chairman and Chief Executive Officer of Emmaus, will present live at VirtualInvestorConferences.com, at 12:30 pm ET on December 16th.

The expanding pharmaceutical and biotechnology sectors worldwide and the rising need for food & drug safety are the key market growth propellers .

Increasing demand for prenatal testing and rising use of blood group typing in forensic laboratories are key factors driving market growth.